Antibody trial suggests a path toward HIV control without daily treatment
A follow up study shows how long acting antibodies may work with the immune system to keep HIV in check.
KRUEGER JAMES G MD STAFFTurn your social into search
We turn your posts into editorial stories that bring new search traffic to rockefeller.edu. Three of yours will be on this page.
Book a demo
rockefelleruniv A large clinical trial led by Rockefeller's Michel Nussenzweig and Marina Caskey shows that long acting antibodies may work with the immune system to control HIV and help reduce the reservoir that would make lifelong treatment necessary. Last year, results from an HIV clinical trial showed that some participants maintained viral control for nearly two years without daily antiretroviral therapy. Now, a follow up study in @nature Medicine reveals how broadly neutralizing antibodies, or bNAbs, kept the virus in check, with lessons that may inform HIV therapy. “The antibodies appear to be teaching the immune system to control HIV,” says Nussenzweig. “It’s almost as if the participants’ own immune activity acts as a second component to the antibodies. Together, the bNAbs and the natural immune response seem to work together to corner the virus.” The latest findings point to a new strategy. using vaccination to prime the immune system to work with bNAbs, while designing novel antibody combinations that make it harder for HIV to develop resistance. This work was supported in part by Rockefeller's @snforg Institute for Global Infectious Disease Research. Learn more at the link in our bio. #science #research #immunology #HIVresearch #HIV #clinicaltrials #bNAbs #scienceforthebenefitofhumanity
A follow up study shows how long acting antibodies may work with the immune system to keep HIV in check.
KRUEGER JAMES G MD STAFFHow it works
Same as today. Nothing changes on Instagram.
We turn your post into a full story in your voice within the hour.
One click publishes it to rockefeller.edu. Nothing goes live without you.
Your stories
Nothing was published anywhere. You decide that. Every word will come from your own posts, your own photos and your own treatments.
HIV Research · From your post
A follow up study shows how long acting antibodies may work with the immune system to keep HIV in check.
“A large clinical trial led by Rockefeller's Michel Nussenzweig and Marina Caskey shows that long acting antibodies may work with the immune system to control HIV and help reduce the reservoir that would make lifelong treatment necessary. Last year, results from an HIV clinical trial showed that some participants maintained viral control for nearly two years without daily antiretroviral therapy. Now, a follow up study in @nature Medicine reveals how broadly neutralizing antibodies, or bNAbs, kept the virus in check, with lessons that may inform HIV therapy. “The antibodies appear to be teaching the immune system to control HIV,” says Nussenzweig. “It’s almost as if the participants’ own immune activity acts as a second component to the antibodies. Together, the bNAbs and the natural immune response seem to work together to corner the virus.” The latest findings point to a new strategy. using vaccination to prime the immune system to work with bNAbs, while designing novel antibody combinations that make it harder for HIV to develop resistance. This work was supported in part by Rockefeller's @snforg Institute for Global Infectious Disease Research. Learn more at the link in our bio. #science #research #immunology #HIVresearch #HIV #clinicaltrials #bNAbs #scienceforthebenefitofhumanity”
Lab Leadership · From your post
A three day workshop this July tackled the parts of running a lab that no one grades in graduate school.
“Early career scientists quickly learn how to design rigorous experiments and interpret data. They’re seldom taught how to juggle projects, manage laboratories, or negotiate salaries. These essential skills were the focus of Managing Science & Scientists, a three day workshop held this July at Rockefeller, sponsored by the Dean’s Office and the Kellen Women’s Entrepreneurship Fund. The workshop was developed specifically for the university and led by faculty from Harvard Business School and UC Berkeley Haas School of Business, with the goal of introducing a cohort of early career researchers to evidence based approaches for addressing the professional realities of research. Learn more at the link in our bio.”
Graduate Research · From your post
A Rockefeller graduate student explains how a wide range of interests led her to study the link between obesity and inflammatory skin disease.
“Rockefeller grad student Natalie Alexander gravitated to science to feed her wide ranging curiosity. Now she’s investigating the connection between obesity and inflammation in skin. a focus she crafted by following her curiosity through different labs and scientific disciplines. “I have always had so many questions about the world, and science is a really practical way to answer those questions,” she says. “I also have a variety of interests, so the interdisciplinary nature of research at Rockefeller lets me not have to choose just one lane.” Learn more at the link in our bio. #science #research #inflammation #obesity #skindisease #gradstudents”
One social post becomes another searchable entry point to Krueger James G MD.
Our own magazine. Clicks and citations from Google Search Console, as of September 15, 2026.
Draft story for rockefeller.edu · HIV Research
A follow up study shows how long acting antibodies may work with the immune system to keep HIV in check.
A year ago, we reported that some participants in an HIV clinical trial maintained viral control for nearly two years without daily antiretroviral therapy. That result raised an obvious question. What was actually happening inside those participants that allowed the virus to stay suppressed once treatment stopped. A new follow up study, led by Michel Nussenzweig and Marina Caskey and published in Nature Medicine, gives us a clearer answer.
The trial centers on broadly neutralizing antibodies, known as bNAbs, which are designed to target HIV directly. But the latest findings suggest these antibodies are not working alone. Instead, they appear to be interacting with each participant's own immune system in a way that produces a more durable form of control, one that persists even after the antibody infusions themselves have ended.
Nussenzweig describes the mechanism in direct terms. The antibodies appear to be teaching the immune system to control HIV. In his words, it is almost as if the participants' own immune activity acts as a second component to the antibodies, with the bNAbs and the natural immune response working together to corner the virus rather than one doing the job alone.
That framing matters because it shifts the goal of treatment. Rather than only neutralizing virus in the bloodstream, the antibodies may be helping the immune system recognize and respond to HIV on its own terms. Over time, that combined pressure appears capable of reducing the viral reservoir, the hidden pool of infected cells that has long made lifelong daily therapy necessary for people living with HIV.
This is why the two year data mattered so much last year. Sustained viral control without daily pills is not simply a convenience. It points to a biological process that could eventually reduce or reshape the treatment burden itself. The new study starts to explain the mechanism behind that outcome, rather than just documenting that it occurred in some participants.
Based on these findings, the research team is now pointing toward a new strategy. One direction involves using vaccination to prime the immune system so it works more effectively alongside bNAbs from the start. Another involves designing novel antibody combinations specifically intended to make it harder for HIV to develop resistance, a persistent challenge in any single antibody or single drug approach.
This work was supported in part by Rockefeller's Institute for Global Infectious Disease Research, reflecting the kind of sustained, collaborative investment that long term HIV research requires. Studies like this one depend on years of clinical trial data, careful immunological analysis, and researchers willing to follow unexpected results, like sustained viral control, back to their underlying cause.
For now, the findings offer a concrete lead rather than a finished treatment. But they reframe what bNAbs might ultimately accomplish, not as a replacement for daily therapy alone, but as a tool that works with the immune system already present in each patient. That combination, antibody and immune response acting together, is the detail this study was built to explain.
Draft story for rockefeller.edu · Lab Leadership
A three day workshop this July tackled the parts of running a lab that no one grades in graduate school.
Every early career scientist learns how to design a clean experiment and defend a result under questioning. Almost none of them are taught how to run a lab, manage a team, or ask for a fair salary. That gap sits quietly under a lot of careers until someone is suddenly in charge of people and budgets with no training for either.
This July we set out to close that gap with Managing Science and Scientists, a three day workshop held here at Rockefeller. It was sponsored by the Dean's Office and the Kellen Women's Entrepreneurship Fund, and it gathered a cohort of early career researchers around a table to talk through the professional realities that come after the bench work is done.
The room itself tells you what kind of session this was. Chairs pulled close, name cards at every seat, laptops and water bottles lined up next to notebooks. A small panel sat at the front fielding questions while the rest of the group faced them directly, the kind of setup built for conversation rather than a lecture delivered from a podium.
Juggling multiple projects at once, managing a laboratory team, negotiating a salary: these are not abstract skills. They are the daily mechanics of a scientific career once someone moves from doing research to directing it. Graduate programs are built around rigor and data, and for good reason, but they rarely make room for the managerial side of the job until it becomes unavoidable.
We did not want a generic leadership seminar bolted onto a science curriculum. The workshop was developed specifically for our university and led by faculty from Harvard Business School and UC Berkeley's Haas School of Business, bringing an evidence based approach to problems that scientists face but rarely get formal instruction in solving well.
That pairing matters. Business schools have spent decades studying negotiation, team management, and organizational behavior with the same rigor scientists apply to their own experiments. Bringing that expertise directly into a research setting means the strategies taught were not theoretical. They were built to map onto the specific pressures of running a laboratory and managing collaborators.
The Kellen Women's Entrepreneurship Fund's involvement points to a deliberate emphasis inside the program. Negotiating a salary or advocating for lab resources is not a skill everyone is taught to practice with equal encouragement, and naming that directly is part of what made this workshop feel less like a general seminar and more like a targeted intervention.
None of this replaces the years spent mastering a technique or defending a dissertation. It sits alongside that training, filling in the parts of a scientific career that determine whether good research actually gets the support, staffing, and compensation it deserves. Details on the workshop and how to learn more are available through the link in our bio.
Draft story for rockefeller.edu · Graduate Research
A Rockefeller graduate student explains how a wide range of interests led her to study the link between obesity and inflammatory skin disease.
Natalie Alexander did not arrive at science through a single defining question. She arrived through many of them, stacked up over years, the kind of restless curiosity that refuses to settle on one subject. That restlessness is now the engine behind her graduate research, which looks at how obesity and inflammation intersect in the skin, a connection that is easy to overlook but not easy to untangle.
Her path into this specific question was not a straight line. She moved through different labs and different scientific disciplines before landing on this focus, treating each stop as a way to test what genuinely held her attention rather than committing early to a single track. That approach shaped both her scientific interests and the kind of researcher she has become.
As she puts it, science offered her a practical outlet for a lifetime of questions about how the world works. Research is not abstract to her. It is a method, a way of taking curiosity and turning it into testable, answerable work rather than letting the questions pile up unresolved.
The connection between obesity and inflammation is well documented in broad terms, but its specific behavior in skin is a narrower and less obvious corner of that story. Choosing to study it there reflects a willingness to work in a space that requires pulling together metabolic biology and dermatological science rather than staying inside one established field.
That willingness to cross disciplines is not incidental to her work, it is central to why she chose Rockefeller in the first place. She has described the interdisciplinary structure of research here as something that lets her avoid picking just one lane, which matters when a question like hers naturally sits at the boundary of several fields rather than comfortably inside one.
That framing says something about how meaningful scientific questions often take shape. They rarely arrive fully formed inside a single discipline. More often they are found at the edges, in the space between fields that do not usually talk to each other, which is exactly where the link between obesity and skin inflammation sits.
Her graduate work is still unfolding, but the throughline is already clear. Wide ranging curiosity is not a detour from focused research, it is what produced the focus in the first place. Moving through different labs was not indecision, it was how she identified the question worth staying with.
What she is studying now, the relationship between obesity and inflammation in skin, is the product of that process rather than a departure from it. It is a reminder that some of the most specific scientific questions come from researchers who were willing, early on, to stay curious about almost everything before narrowing in on one thing worth answering in depth.
Keep reading